169 related articles for article (PubMed ID: 37559025)
1. Brachytherapy for targeting the immune system in cervical cancer patients.
Linares I; Berenguer Frances MÁ; Cañas R; Najjari D; Gutiérrez C; Marín S; Comas S; Guedea F; Pujol M
BMC Immunol; 2023 Aug; 24(1):23. PubMed ID: 37559025
[TBL] [Abstract][Full Text] [Related]
2. Radiobiological optimization comparison between pulse-dose-rate and high-dose-rate brachytherapy in patients with locally advanced cervical cancer.
Annede P; Dumas I; Schernberg A; Tailleur A; Fumagalli I; Bockel S; Mignot F; Kissel M; Deutsch E; Haie-Meder C; Chargari C
Brachytherapy; 2019; 18(3):370-377. PubMed ID: 30797698
[TBL] [Abstract][Full Text] [Related]
3. Outcome analysis of HDR compared to PDR IGABT in locally advanced cervical cancer: a single-center cohort analysis.
Hermesse J; Pleyers C; Gennigens C; De Cuypere M; Lovinfosse P; Seidel Statistician L; Coucke P; Kridelka F
Strahlenther Onkol; 2023 Feb; 199(2):141-148. PubMed ID: 35943555
[TBL] [Abstract][Full Text] [Related]
4. Changes of CD68, CD163, and PD-L1 tumor expression during high-dose-rate and pulsed-dose-rate brachytherapy for cervical cancer.
Berenguer Frances MA; Linares-Galiana I; Cañas Cortés R; Marín I Borrás S; Gutiérrez Miguélez C; Najjari D; Slocker A; Bellobí C; Santacana M; Pané Foix M; Alonso MH; Navarro-Martin A; Comas Antón S; Guedea F
Brachytherapy; 2020; 19(1):51-59. PubMed ID: 31690516
[TBL] [Abstract][Full Text] [Related]
5. American Brachytherapy Task Group Report: A pooled analysis of clinical outcomes for high-dose-rate brachytherapy for cervical cancer.
Mayadev J; Viswanathan A; Liu Y; Li CS; Albuquerque K; Damato AL; Beriwal S; Erickson B
Brachytherapy; 2017; 16(1):22-43. PubMed ID: 28109631
[TBL] [Abstract][Full Text] [Related]
6. Pulsed dose rate and fractionated high dose rate brachytherapy: choice of brachytherapy schedules to replace low dose rate treatments.
Visser AG; van den Aardweg GJ; Levendag PC
Int J Radiat Oncol Biol Phys; 1996 Jan; 34(2):497-505. PubMed ID: 8567354
[TBL] [Abstract][Full Text] [Related]
7. Does an Algorithmic Approach to Using Brachytherapy and External Beam Radiation Result in Good Function, Local Control Rates, and Low Morbidity in Patients With Extremity Soft Tissue Sarcoma?
Klein J; Ghasem A; Huntley S; Donaldson N; Keisch M; Conway S
Clin Orthop Relat Res; 2018 Mar; 476(3):634-644. PubMed ID: 29443850
[TBL] [Abstract][Full Text] [Related]
8. BAIRDA: a novel
Chow B; Warkentin B; Nanda K; Ghosh S; Huang F; Gamper AM; Menon G
Phys Med Biol; 2022 Feb; 67(4):. PubMed ID: 35086068
[No Abstract] [Full Text] [Related]
9. Second primary malignancies after radiotherapy including HDR (252)Cf brachytherapy for cervical cancer.
Samerdokiene V; Valuckas KP; Janulionis E; Atkocius V; Rivard MJ
Brachytherapy; 2015; 14(6):898-904. PubMed ID: 26194049
[TBL] [Abstract][Full Text] [Related]
10. The effect of alternative biological modelling parameters (α/β and half time of repair T ½ ) on reported EQD2 values in the treatment of advanced cervical cancer.
De Leeuw AA; Van de Kamer JB; Moerland MA; Philippens ME; Jürgenliemk-Schulz IM
Radiother Oncol; 2011 Nov; 101(2):337-42. PubMed ID: 21742393
[TBL] [Abstract][Full Text] [Related]
11. Dosimetric comparison of inverse optimisation methods versus forward optimisation in HDR brachytherapy of breast, cervical and prostate cancer.
Fröhlich G; Geszti G; Vízkeleti J; Ágoston P; Polgár C; Major T
Strahlenther Onkol; 2019 Nov; 195(11):991-1000. PubMed ID: 31482321
[TBL] [Abstract][Full Text] [Related]
12. Brachytherapy boost in anal canal cancer - A GEC ESTRO PDR task force meta-analysis.
Annede P; Ferre M; Kirisits C; Pieters BR; Schmid M; Strnad V; Westerveld H; Chargari C
Clin Transl Radiat Oncol; 2023 Mar; 39():100589. PubMed ID: 36785565
[TBL] [Abstract][Full Text] [Related]
13. Redefining the role of pulsed-dose-rate brachytherapy in cervical cancer treatment using a preplanned approach.
Annede P; Robert C; Espenel S; Dumas I; Chargari C
Brachytherapy; 2024; 23(2):107-114. PubMed ID: 38105154
[TBL] [Abstract][Full Text] [Related]
14. Dosimetry of local failure with single dose 19 Gy high-dose-rate brachytherapy for prostate cancer.
Armstrong S; Tsang Y; Lowe G; Tharmalingam H; Alonzi R; Ostler P; Hughes R; Hoskin P
Radiother Oncol; 2021 Apr; 157():93-98. PubMed ID: 33493500
[TBL] [Abstract][Full Text] [Related]
15. A dosimetric comparison of Volumetric Modulated Arc Therapy (VMAT) and High Dose Rate (HDR) brachytherapy in localized cervical cancer radiotherapy.
Wali L; Helal A; Darwesh R; Attar M
J Xray Sci Technol; 2019; 27(3):473-483. PubMed ID: 30958322
[TBL] [Abstract][Full Text] [Related]
16. Preliminary Study of the Effect of Stereotactic Body Radiotherapy (SBRT) on the Immune System in Lung Cancer Patients Unfit for Surgery: Immunophenotyping Analysis.
Navarro-Martín A; Galiana IL; Berenguer Frances MA; Cacicedo J; Cañas Cortés R; Comas Anton S; Padrones Sánchez S; Bolívar Cuevas S; Parry R; Guedea Edo F
Int J Mol Sci; 2018 Dec; 19(12):. PubMed ID: 30544863
[TBL] [Abstract][Full Text] [Related]
17. Pathologic complete remission after preoperative high-dose-rate brachytherapy in patients with operable cervical cancer: preliminary results of a prospective randomized multicenter study.
Vízkeleti J; Vereczkey I; Fröhlich G; Varga S; Horváth K; Pulay T; Pete I; Nemeskéri C; Mayer Á; Sipos N; Kásler M; Polgár C
Pathol Oncol Res; 2015 Apr; 21(2):247-56. PubMed ID: 25011515
[TBL] [Abstract][Full Text] [Related]
18. Primary radiotherapy of stage IIA/B-IIIB cervical carcinoma. A comparison of continuous versus sequential regimens.
Mayer A; Nemeskéri C; Petneházi C; Borgulya G; Varga S; Naszály A
Strahlenther Onkol; 2004 Apr; 180(4):209-15. PubMed ID: 15057431
[TBL] [Abstract][Full Text] [Related]
19. Effect of blood transfusion during radiotherapy on the immune function of patients with cancer of the uterine cervix: role of interleukin-10.
Santin AD; Bellone S; Palmieri M; Bossini B; Dunn D; Roman JJ; Pecorelli S; Cannon M; Parham GP
Int J Radiat Oncol Biol Phys; 2002 Dec; 54(5):1345-55. PubMed ID: 12459356
[TBL] [Abstract][Full Text] [Related]
20. Comparison of late toxicity between continuous low-dose-rate and pulsed-dose-rate brachytherapy in cervical cancer patients.
Bachtiary B; Dewitt A; Pintilie M; Jezioranski J; Ahonen S; Levin W; Manchul L; Yeung I; Milosevic M; Fyles A
Int J Radiat Oncol Biol Phys; 2005 Nov; 63(4):1077-82. PubMed ID: 16024181
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
